Authorization

Addex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020

Geneva, Switzerland, August 6, 2020A - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that Tim Dyer, Chief Executive Officer,A will participate in the BTIG Virtual Biotechnology Conference taking place on August 10 a?? 11, 2020.Mr. Dyer will participate and present Addex on August 10, 2020 at 10:30 AM ET. You can follow the event by following this link.Mr. Dyer will also be available for one-on-one meetings during the conference. Meetings can be requested via the BTIG virtual conference system for those who registered to participate. About Addex TherapeuticsAddex TherapeuticsA is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is scheduled to enter a pivotal registration clinical trial for Parkinsona??s disease levodopa induced dyskinesia (PD-LID). In parallel, dipraglurant's therapeutic use in dystonia is being investigated in preclinical models. Addex's second clinical program ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with our partner Janssen Pharmaceuticals, Inc., scheduled to enter a Phase 2a proof of concept clinical study for the treatment of epilepsy. In addition, Addexa??s GABABA PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABABA PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsona??s disease and mGlu3 PAM for neurodegenerative disorders.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930